Evidence map›Paper›PMID 41479041›Full record

ReviewSub-cellular biochemistry2026

The Epigenetic Angle in the Precision Medicine Era for Blood Disorder Advancements.

Nadia M Hamdy, Ahmed I Abulsoud, Nehal I Rizk, Tohada M Al-Noshokaty, Mohamed Bakr Zaki, Ahmed S Sultan, Ahmed S Doghish

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Sub-cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Nadia M HamdyBiochemistry and Molecular Biology Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Ahmed I AbulsoudFaculty of Pharmacy, Biochemistry Department, Heliopolis University, Cairo, Egypt.
Nehal I RizkDepartment of Biochemistry, Faculty of Pharmacy and Drug Technology, Egyptian Chinese University, Cairo, Egypt.
Tohada M Al-NoshokatyBiochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Mohamed Bakr ZakiDepartment of Biochemistry, Faculty of Pharmacy, University of Sadat City, Menoufia, Egypt.
Ahmed S SultanDepartment of Oncology and Diagnostic Sciences, College of Dental Surgery, University of Maryland Baltimore, Baltimore, MD, USA.
Ahmed S DoghishBiochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt. ahmed_doghish@azhar.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This work examined the integration of epigenetics and precision medicine in the management of various blood disorders, including anemias, antiphospholipid syndrome, hemochromatosis, hemophilia, leukemia, lymphoma, multiple myeloma, porphyria, thalassemia, thrombocytopenia, thrombocytosis, polycythemia, von Willebrand disease, and coagulopathy. It begins with an overview of key concepts and the significance of precision medicine in treating blood diseases, supported by current statistics. The role of noncoding RNAs (ncRNAs) is highlighted, detailing their mechanisms of action and clinical implications as potential biomarkers and therapeutic targets. Additionally, the chapter explores natural products used in personalized medicine, examining their sources, mechanisms, and successful case studies in blood disorders. A comprehensive review of recent clinical trials provides insights into the impact of innovative therapies and FDA approvals on treatment protocols, emphasizing the importance of combination therapies. Future directions address emerging research technologies such as clustered regularly interspaced short palindromic repeats (CRISPR) and ethical considerations surrounding genetic testing and patient consent. The synthesis of findings underscores the contributions of epigenetics and precision medicine to blood disease treatment, advocating for interdisciplinary research and ongoing education to enhance patient care and outcomes.

Indexed as

Epigenesis, GeneticHematologic DiseasesPrecision MedicineHumansRNA, UntranslatedRNA, UntranslatedBiomarkersBlood cancerBlood disordersEpigeneticsLeukemialncRNAsMicroRNAsMultiple myelomaPMTherapeutic targets

Identifiers

PMID41479041

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.